Overview

• The Consello de la Xunta authorized the acquisition and President Alfonso Rueda announced it after the meeting.
• Health chief Antonio Gómez Caamaño cited €65 million in savings from Sergas’s centralized procurement to justify reinvestment in advanced therapies.
• The plan will bring two CAR‑T medicines into the public health system at an estimated cost of about €400,000 per patient, according to officials.
• Multiple myeloma is identified by the Xunta as Galicia’s second most common hematologic cancer targeted by the program.
• Rueda said local manufacturing of advanced therapies is planned to start next year in Santiago.